Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent to take part in the study and its related tests.
• People who have been diagnosed with pancreatic cancer (PDAC) that has spread to other parts of the body, confirmed by a tissue or cell sample.
• People who have not yet received any treatment (chemotherapy, radiation, or surgery) for their pancreatic cancer.
• People of any sex aged 18 or older.
• People who are generally well enough to carry out light activity and care for themselves (a doctor will assess this using a standard scale called ECOG, with a score of 0 or 1 required).
• People whose cancer can be measured on imaging scans, according to standard criteria called RECIST 1.1.
• People enrolled in the PAXG treatment group must have had a specific enzyme called DPD already tested and documented.
• People whose blood counts are within acceptable ranges — including white blood cells, platelets, and haemoglobin (a doctor will check these).
• People whose liver function blood tests are within acceptable ranges (a doctor will check these).
• People whose kidney function is within acceptable ranges, based on blood tests or a calculated kidney function score (a doctor will check this).

Who may not be able to join:

• People who have had another cancer diagnosed within the past year, with exceptions for certain treated skin cancers or cervical pre-cancer.
• People who have already received chemotherapy or other medical treatments for their metastatic pancreatic cancer (previous chemotherapy after surgery may be acceptable if it ended more than 6 months ago — confirm with trial site).
• People who have previously been treated with a type of drug called an HDAC inhibitor, or with medications that work in a similar way, such as valproic acid (an epilepsy and mood medication).
• People who have used statins, fibrates, or any cholesterol-lowering medication at any point in the 3 months before joining the study.
• People with a known allergic reaction to statins or to any other medications used in this trial.
• People who have had major surgery within 4 weeks before enrolling.
• People who are pregnant or breastfeeding.
• People whose cancer has spread to the brain.
• People with hepatitis or any serious liver condition.
• People with severe or poorly controlled illness, or any other condition that the trial doctor considers would make participation unsafe or interfere with the study.
• People with a heart condition called long QT syndrome, or whose heart rhythm measurement (QTc interval) is above a certain level, or who are taking medications that affect heart rhythm (confirm with trial site for the specific medication list).
• People with a history of difficulty cooperating with medical treatment, or any condition that may affect their ability to understand and consent to the study.
• People who have participated in another clinical drug or medical device trial within 30 days before the start of treatment.
• People who are unable to swallow oral (tablet/capsule) medications, who require feeding through a vein, who have had surgery that affects how the gut absorbs food or medicine, or who have an active stomach ulcer.
• People who are sexually active and of childbearing potential but are unwilling to use contraception during the study and for 6 months after the last treatment.

Important: Always verify eligibility with the trial site directly before applying.